San Diego-based Aethlon Medical Inc., a medical device company developing therapies for infectious diseases and cancer, announced that the U.S. Food and Drug Administration (FDA) has approved a clinical protocol to treat Ebola-infected individuals in the U.S. with the Aethlon Hemopurifier.

The Hemopurifier is a biofiltration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals.

The device is fitted into a dialysis machine, which filters blood for people with kidney disease. In the case of Ebola, the device removes viruses, plus the proteins that suppress the immune system, from the bloodstream, according to Jim Joyce, CEO and founder of Aethlon.

The Ebola treatment protocol resulted from the submission of a supplement to an Investigation Device Exemption (IDE) previously approved by the FDA.

Time Magazine recently named the Aethlon Hemopurifier as one of the 25 best inventions of 2014. The magazine also included the Hemopurifier as one of the 11 most remarkable advances in healthcare in 2014.